IMUX
$16.62
Immunic
($1.12)
(6.31%)
IMUX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.61)
Revenue:  $0.00 Mil
Thursday
Nov 5
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IMUX reports earnings?
Beat
Meet
Miss

Where is IMUX's stock price going from here?
Up
Flat
Down
Stock chart of IMUX
Analysts
Summary of analysts' recommendations for IMUX
Score
Grade
Pivots
Resistance
$19.60
$18.97
$17.80

$17.16

Support
$15.99
$15.36
$14.19
Tweet
Growth
Description
Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States.